Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
42.69
+1.75 (+4.27%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
No Early Relief for JW Therapeutics from Cancer Wonder Drug
September 07, 2022
Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down. Large-scale market expansion is not going to be easy The...
Via
Benzinga
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 01, 2022
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.
Via
Investor's Business Daily
Legend Biotech Announces Participation in Upcoming Investor Conferences
August 19, 2022
From
Legend Biotech
Via
Business Wire
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
August 16, 2022
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for
Via
Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
August 05, 2022
From
Legend Biotech Corporation
Via
Business Wire
Short Volatility Alert: Legend Biotech Corporation
June 24, 2022
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The...
Via
Benzinga
Legend Biotech Shares Move Higher After Bullish BMO Pitch
June 17, 2022
Via
Benzinga
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
August 04, 2022
From
Legend Biotech
Via
Business Wire
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
July 30, 2022
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...
Via
Talk Markets
PayPal, Alphabet And Some Other Big Stocks Recording Gains On Wednesday
July 28, 2022
U.S. stocks closed sharply higher on Wednesday, with the Dow Jones jumping more than 400 points. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Short Volatility Alert: Legend Biotech Corporation
June 17, 2022
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The...
Via
Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
July 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Walmart, Shopify And Some Other Big Stocks Recording Losses On Tuesday
July 27, 2022
U.S. stocks closed lower on Monday, with the Nasdaq Composite dropping more than 200 points. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Legend Biotech Corporation Announces Pricing of Public Offering
July 26, 2022
From
Legend Biotech Corporation
Via
Business Wire
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
July 25, 2022
Gainers
Via
Benzinga
Legend Biotech Corporation Announces Proposed Public Offering
July 25, 2022
From
Legend Biotech Corporation
Via
Business Wire
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
June 06, 2022
This biotech stock launched in February to work on CAR-T treatments.
Via
Investor's Business Daily
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
June 04, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
June 03, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
June 01, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022
From
Legend Biotech
Via
Business Wire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
May 28, 2022
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...
Via
Talk Markets
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
May 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 26, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
May 18, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
May 09, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
May 06, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Appointment of Global Head of Research and Early Development
April 01, 2022
From
Legend Biotech Corporation
Via
Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
May 05, 2022
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.